98%
921
2 minutes
20
This clinical practice guideline addresses the prevention, diagnosis, and management of hypoparathyroidism (HypoPT) and provides evidence-based recommendations. The HypoPT task forces included four teams with a total of 50 international experts including representatives from the sponsoring societies. A methodologist (GG) and his team supported the taskforces and conducted the systematic reviews. A formal process following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology and the systematic reviews provided the structure for seven of the guideline recommendations. The task force used a less structured approach based on narrative reviews for 20 non-GRADEd recommendations. Clinicians may consider postsurgical HypoPT permanent if it persists for >12 months after surgery. To predict which patients will not develop permanent postsurgical HypoPT, we recommend evaluating serum PTH within 12 to 24 hours post total thyroidectomy (strong recommendation, moderate quality evidence). PTH > 10 pg/mL (1.05 pmol/L) virtually excludes long-term HypoPT. In individuals with nonsurgical HypoPT, genetic testing may be helpful in the presence of a positive family history of nonsurgical HypoPT, in the presence of syndromic features, or in individuals younger than 40 years. HypoPT can be associated with complications, including nephrocalcinosis, nephrolithiasis, renal insufficiency, cataracts, seizures, cardiac arrhythmias, ischemic heart disease, depression, and an increased risk of infection. Minimizing complications of HypoPT requires careful evaluation and close monitoring of laboratory indices. In patients with chronic HypoPT, the panel suggests conventional therapy with calcium and active vitamin D metabolites as first-line therapy (weak recommendation, low-quality evidence). When conventional therapy is deemed unsatisfactory, the panel considers the use of PTH. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jbmr.4691 | DOI Listing |
Calcif Tissue Int
August 2025
Department of Trauma, Orthopedics and Reconstructive Surgery, Research and Development, University Medical Center Göttingen, Göttingen, Germany.
Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by low parathyroid hormone (PTH) levels, hypocalcemia, hyperphosphatemia, reduced active vitamin D (1,25-OH2 vitamin D), and hypercalciuria. Due to its rarity, non-specialized physicians often lack experience managing HypoPT. To address this, expert consensus statements were developed for the DACH region (Germany, Austria, Switzerland), considering regional differences and high HypoPT incidence.
View Article and Find Full Text PDFBMC Endocr Disord
July 2025
Department of Cardiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, P.R. China.
Background: Hypoparathyroidism (HypoPT) is a rare endocrine disease characterized by hypocalcemia, hyperphosphatemia, and insufficient or no parathyroid hormone (PTH) secretion. Hypoparathyroidism-induced chronic hypocalcemia may lead to cardiovascular complications, including myocardial dysfunction and arrhythmias. Interventricular septal dissecting aneurysm, a rare cardiac anomaly, typically arises following structural or ischemic heart disease.
View Article and Find Full Text PDFEur J Endocrinol
July 2025
Takeda Development Center Americas, Inc., Cambridge, MA 02142, United States.
Objective: To assess the impact of recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] compared with placebo, in combination with conventional therapy with vitamin D and/or calcium supplements, on health-related quality of life (HRQoL) in patients with symptomatic chronic hypoparathyroidism (cHypoPT).
Design: Randomized, double-blind, placebo-controlled, phase 3b-4 study (ClinicalTrials.gov ID: NCT03324880).
J Endocr Soc
September 2025
MVZ endokrinologikum Göttingen, Center for Endocrinology, Osteology, Rheumatology, Nulear Medicine and Human Genetics, Göttingen 37075, Germany.
Background: Replacement therapy with recombinant human PTH (rhPTH1-84) represents a causal treatment for patients with chronic hypoparathyroidism (HypoPT). Recently, palopegteriparatide (TransCon PTH), a novel long-acting drug with slow release of PTH1-34, was approved by the European Medicines Agency and Food and Drug Administration for treatment of HypoPT. To date, no data exist on the treatment switch from rhPTH1-84 to TransCon PTH.
View Article and Find Full Text PDFAging Clin Exp Res
July 2025
FirmoLab, Fondazione FIRMO Onlus and Stabilimento Chimico Farmaceutico Militare, Florence, Italy.
Background: Chronic hypoparathyroidism (HypoPT) is a rare endocrine condition, having variable etiology, characterized by low parathyroid hormone levels, leading to reduced calcium levels and increased phosphorus values in the blood. Bone health is an important clinical aspect to be considered in patients with HypoPT, whose skeleton is exposed both to the HypoPT-induced alteration of bone mass and microarchitecture, and to the natural occurrence and progression of bone mass loss due to menopause and ageing.
Aim: Investigating bone status in a cohort of Italian HypoPT patients from the HypoparaNET database.